1 published article · Updated continuously
5 trials tracked for Rotavirus infection: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 14 citations.
Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Rotarix administration demonstrates significant immunogenicity in infants. Evidence shows high rates of successful vaccine take, defined as either positive fecal vaccine-strain virus shedding or rotavirus-specific plasma IgA seroconversion 1.
The Rotarix vaccine is associated with robust seroprotection and antibody responses. Specifically, subjects demonstrated anti-polyribosyl ribitol phosphate (Anti-PRP) antibody concentrations above the 0.15 µg/mL cut-off, as well as significant seroprotection at the 1.0 µg/mL threshold 3. Furthermore, Rotarix elicited statistically significant seroprotective responses to Anti-PT, Anti-FHA, and Anti-PRN antibodies (p=<.0001) 3.
Safety profiles for Rotarix have been established in large cohorts; studies observed a range of solicited systemic reactions within 8 days post-vaccination across various study arms 2.
AI synthesis of 5 cited trials, updated Jul 5, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
